Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

9 terminated/withdrawn out of 45 trials

Success Rate

76.3%

-10.2% vs industry average

Late-Stage Pipeline

33%

15 trials in Phase 3/4

Results Transparency

14%

4 of 29 completed trials have results

Key Signals

2 recruiting4 with results9 terminated

Enrollment Performance

Analytics

Phase 2

10(37.0%)

Phase 3

10(37.0%)

Phase 4

5(18.5%)

Phase 1

1(3.7%)

N/A

1(3.7%)

27Total

Phase 2(10)

Phase 3(10)

Phase 4(5)

Phase 1(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (45)

Showing 20 of 45 trials

NCT03731832Phase 2Completed

Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma

Role: lead

NCT04257448Phase 1Completed

Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer

Role: lead

NCT04833114Phase 3Active Not Recruiting

Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

Role: lead

NCT05181592Phase 3Active Not Recruiting

Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.

Role: lead

NCT01347216Recruiting

COMPERA / COMPERA-KIDS

Role: collaborator

NCT03110432Completed

Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry

Role: lead

NCT04062656Phase 2Unknown

Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG

Role: collaborator

NCT02164578Phase 3Completed

Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Subclinical Inflammation and High Cardiovascular Risk

Role: lead

NCT04061239Phase 2Recruiting

Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML

Role: lead

NCT02699151Completed

INvestigating SIGnificant Health TrendS in the Management of Superficial Vein Thrombosis

Role: lead

NCT03807479Phase 2Terminated

Study in Patients With Chronic Leukemia

Role: lead

NCT03054181Completed

Facilitated Immunoglobulin Administration Registry and Outcomes Study (FIGARO)